[
  {
    "ts": "2025-12-11T01:06:47+00:00",
    "headline": "Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves",
    "summary": "Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...",
    "url": "https://finance.yahoo.com/news/why-analysts-think-merck-could-010647122.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8517f8cd-59ee-3c97-a724-81601c917cd6",
      "content": {
        "id": "8517f8cd-59ee-3c97-a724-81601c917cd6",
        "contentType": "STORY",
        "title": "Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves",
        "description": "",
        "summary": "Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...",
        "pubDate": "2025-12-11T01:06:47Z",
        "displayTime": "2025-12-11T01:06:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-think-merck-could-010647122.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-think-merck-could-010647122.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:33:01+00:00",
    "headline": "Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1",
    "summary": "​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]",
    "url": "https://finance.yahoo.com/news/merck-co-mrk-gets-conditional-123301462.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fdfa8729-2b93-34eb-8bc2-2c8e13da66ca",
      "content": {
        "id": "fdfa8729-2b93-34eb-8bc2-2c8e13da66ca",
        "contentType": "STORY",
        "title": "Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1",
        "description": "",
        "summary": "​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]",
        "pubDate": "2025-12-11T12:33:01Z",
        "displayTime": "2025-12-11T12:33:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzRhrl6IP..dz_8NtaA67g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C.KM1e7Q4T5mCkqt60S1Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-gets-conditional-123301462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-gets-conditional-123301462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T14:13:33+00:00",
    "headline": "Stock Market Today: Dow Turns Lower On Surprise Jobless Claims Data; Oracle Plunges On Earnings (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index wavered Thursday after surprise weekly jobless claims. AI stock Oracle plunged on earnings.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobless-claims-oracle-orcl-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "4d68f763-5908-3016-a53c-c3b53659e6c9",
      "content": {
        "id": "4d68f763-5908-3016-a53c-c3b53659e6c9",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Turns Lower On Surprise Jobless Claims Data; Oracle Plunges On Earnings (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index wavered Thursday after surprise weekly jobless claims. AI stock Oracle plunged on earnings.",
        "pubDate": "2025-12-11T14:13:33Z",
        "displayTime": "2025-12-11T14:13:33Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4d68f763-5908-3016-a53c-c3b53659e6c9/stock-market-today-dow-turns.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RkIoP5aIoaWmMg1KUnpqdg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wh39EUbEziJHgMn.DZRyfQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobless-claims-oracle-orcl-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "CIEN"
            },
            {
              "symbol": "ADBE"
            },
            {
              "symbol": "SNPS"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "V"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:49:00+00:00",
    "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
    "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
    "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b79aa32-9f8b-3905-9def-46d9a2e0d275",
      "content": {
        "id": "6b79aa32-9f8b-3905-9def-46d9a2e0d275",
        "contentType": "STORY",
        "title": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
        "description": "",
        "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
        "pubDate": "2025-12-11T12:49:00Z",
        "displayTime": "2025-12-11T12:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]